Article Details
Retrieved on: 2021-08-18 15:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ACTIV-3 Critical Care is Evaluating ZYESAMI™ and Remdesivir, in Critical COVID-19 Patients, as Monotherapy and in Combination Against Placebo.
Article found on: finance.yahoo.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here